Get the Stockscreener App
1.30
4.84%
+0.06
After Hours:
1.20
-0.10
-7.69%
Hepion Pharmaceuticals Inc stock is currently priced at $1.30, with a 24-hour trading volume of 28,040.
It has seen a +4.84% increased in the last 24 hours and a -38.97% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.20 pivot point. If it approaches the $1.34 resistance level, significant changes may occur.
Previous Close:
$1.24
Open:
$1.195
24h Volume:
28,040
Market Cap:
$7.11M
Revenue:
-
Net Income/Loss:
$-44.68M
P/E Ratio:
-0.1087
EPS:
-11.96
Net Cash Flow:
$-36.70M
1W Performance:
+3.17%
1M Performance:
-38.97%
6M Performance:
-57.79%
1Y Performance:
-81.51%
1D Range:
$1.195
$1.35
52W Range:
$1.115
$20.66
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
732 902 4000
Address
399 Thornall Street, First Floor, Edison
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) A Volatile Stock? - Yahoo Canada Shine On
Yahoo Canada Shine On
Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock? - Yahoo News UK
Yahoo News UK
Hepion shelves Phase II NASH trial amid shallow cash resources - Clinical Trials Arena
Clinical Trials Arena
S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings - Moolec Science (NASDAQ:MLEC), Hepion ... - Benzinga
Benzinga
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
GlobeNewswire Inc.
Hepion ends Phase 2 study for NASH drug due to cash restraints (NASDAQ:HEPA) - Seeking Alpha
Seeking Alpha
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Hepion Pharmaceuticals Inc (HEPA) Net Income 2024
HEPA net income (TTM) was -$44.68 million for the quarter ending September 30, 2023, a +0.96% increase year-over-year.
Hepion Pharmaceuticals Inc (HEPA) Cash Flow 2024
HEPA recorded a free cash flow (TTM) of -$36.70 million for the quarter ending September 30, 2023, a +2.26% increase year-over-year.
Hepion Pharmaceuticals Inc (HEPA) Earnings per Share 2024
HEPA earnings per share (TTM) was -$12.42 for the quarter ending September 30, 2023, a -4.55% decline year-over-year.
Hepion Pharmaceuticals Inc Stock (HEPA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wijngaard Peter | Director |
Nov 24 '23 |
Buy |
3.09 |
2,500 |
7,725 |
7,001 |
| Wijngaard Peter | Director |
Sep 19 '23 |
Buy |
5.64 |
1,000 |
5,640 |
4,501 |
| Foster Robert T | CEO and Director |
Sep 18 '23 |
Buy |
5.60 |
1,600 |
8,960 |
50,470 |
| Wijngaard Peter | Director |
Sep 15 '23 |
Buy |
5.60 |
2,000 |
11,201 |
3,501 |
| Foster Robert T | CEO,CSO and Director |
Sep 15 '23 |
Buy |
5.40 |
1,600 |
8,640 |
48,870 |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
0.77%
1.20%
Cap:
|
Volume (24h):